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Objectives. This study was designed to determine the risk of
performing percutaneous transluminal coronary angioplasty
(PTCA) at the time of diagnostic catheterization (“combined
procedures”).
Background. Health care providers are under increasing pres-
sure to combine diagnostic and interventional coronary proce-
dures to reduce costs. However, the risk associated with combined
procedures has not been rigorously assessed.
Methods. A multicenter cohort study of 35,700 patients under-
going elective PTCA from 1992 through 1995 was performed to
determine the risk of major complications (myocardial infarction,
emergency coronary artery bypass graft surgery or death) from
combined relative to staged procedures (i.e., performing PTCA at
a session subsequent to diagnostic catheterization).
Results. The risks of major complications from combined and
staged procedures were 2.0% and 1.6%, respectively (unadjusted
odds ratio [OR] 1.28, 95% confidence interval [CI] 1.05 to 1.57).
After adjusting for clinical and angiographic differences and
clustering by laboratory, the risk from combined procedures was
not significantly elevated (multivariable OR 1.18, 95% CI 0.89 to
1.55). However, several subgroups of patients did have an in-
creased risk from combined procedures: patients with multivessel
disease (multivariable OR 1.64, 95% CI 1.13 to 2.39); women
(multivariable OR 1.64, 95% CI 1.05 to 2.55); patients >65 years
old (multivariable OR 1.40, 95% CI 1.02 to 1.93); and patients
undergoing multilesion PTCA (multivariable OR 1.53, 95% CI
1.06 to 2.21). The risk of combined relative to staged procedures
decreased over the 4-year period (multivariable p 5 0.029).
Conclusions. Combining PTCA with diagnostic catheterization
appears to be safe in many patients. However, several subgroups
of patients may be at increased risk. Careful patient selection will
most likely remain critical to ensuring the safety of combined
procedures.
(J Am Coll Cardiol 1997;30:193–200)
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There are .400,000 percutaneous transluminal coronary an-
gioplasty (PTCA) procedures performed each year in the
United States, at an estimated cost of 6 billion dollars (1).
Health care providers are under intense pressure from third-
party payers to reduce the cost associated with PTCA (2). One
proposed cost reduction strategy is to perform PTCA at the
time of the initial diagnostic catheterization (“combined,” “ad
hoc” or “add-on” procedures [3,4]). Along with the potential
for decreasing length of hospital stay and costs (3), these
“combined” PTCAs may also reduce the risk of peripheral
vascular complications and patient exposure to radiation and
contrast agents (3).
However, the potential benefits of performing combined
procedures must be weighed against their possible risks. Per-
forming PTCA immediately after a diagnostic procedure in-
volves prolongation of the catheterization procedure and may
not allow for as careful an assessment of the indications for or
technical difficulty of the procedure as may occur in “staged”
procedures (i.e., performing the diagnostic catheterization and
subsequently having the patient return to the catheterization
laboratory for PTCA if clinically indicated [5]). The American
College of Cardiology (ACC) and American Heart Association
(AHA) recommend that combined PTCA is “particularly
suited” for patients with unstable angina who cannot be
stabilized, patients with restenosis after previous angioplasty
and patients undergoing PTCA for acute myocardial infarction
(AMI). However, in the many other patients who might be
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candidates for combined PTCA, there are few data to support
the use of this procedure. Studies that have assessed the risk of
combined procedures in these patients have been limited by
their small sample sizes (3,4,6–9), their lack of a control group
(6,7,9), their performance in only single institutions (many of
which had specific protocols to try to ensure the safety of
combining PTCA with diagnostic angiography [8,9]) and their
highly selected patient groups (6,7). Thus, there remains
debate (8–11) over the proper use of combined procedures at
a time when economic forces are creating increasing pressure
to do more (3,4,8,9). Before recommendations are made to
encourage the routine use of combined procedures, it is
critically important to assure that patients are not unknowingly
placed at increased risk.
Thus, this study was designed to 1) determine if the
performance of combined procedures increases the risk of
major complications compared with staged procedures; and 2)
explore which patient subgroups may be at higher risk from
combined relative to staged procedures.
Methods
Data base. This study used the 1992 through 1995 registries
of the Society for Cardiac Angiography and Interventions
(SCA&I). The SCA&I Registry, established in 1979, is a
voluntary, prospective, multicenter, data collection instrument
allowing individual laboratories and operators to track their
activity. Details of the participating laboratories, data collec-
tion techniques and variable definitions have been previously
reported (12–14). An independent review of 18 laboratories
contributing 56% of procedures to the 1992 Registry con-
firmed that more than 99% of procedures performed at these
laboratories were entered into the data base.
Patient groups and laboratories. From January 1, 1992
through December 31, 1995, a total of 54,607 balloon angio-
plasty procedures were performed in 61 centers participating
in the SCA&I Registries. Twenty-three centers contributed
data to all 4 years of the Registry. Because of intrinsic
differences in the risk of complications with devices other than
balloon catheters (15) and the lack of information in the data
base on whether stents (the most commonly used “other
device”) were used as planned or bailout therapy, only balloon
procedures were included in this analysis. Repeat PTCAs
(13,594 procedures) also were excluded because 1) patients
undergoing a repeat PTCA represent a lower risk group than
patients undergoing a first PTCA (16); and 2) it was not
possible to determine if these repeat PTCAs were performed
on restenotic or de novo lesions (a potentially important
predictor of complications [17]). To eliminate the bias that
could result from including combined procedures that were
performed either because of hemodynamic instability or a
complication that occurred during diagnostic angiography or
because of indications that could be associated with an in-
creased risk of complications, we excluded patients undergoing
emergency PTCA (any unplanned PTCA [14]), patients in
shock (any hemodynamic instability before PTCA [14]) and
PTCAs performed within 24 h after an AMI, regardless of
whether PTCA was combined or staged (total of 5,313 patients
excluded, leaving 35,700 patients for this study). To identify
subgroups that might be at increased risk from combined
procedures, patients were further divided into prespecified risk
groups on the basis of age, gender, ACC/AHA Task Force
classification of lesion type (5), number of lesions attempted,
laboratory volume and the presence or absence of heart
failure, diabetes mellitus, AMI within 2 to 14 days before
PTCA, unstable angina and multivessel disease.
Study variables. Combined procedures were defined as
coronary angioplasty performed during the same session as a
diagnostic catheterization. All other procedures were consid-
ered “staged” procedures. The data entry system used for this
Registry required that this variable be recorded for all patients.
The primary outcome variable, “major complication,” was
defined as any one or more of the following: 1) emergency
coronary artery bypass graft surgery (CABG) as a result of the
procedure; 2) death occurring any time during the hospital
period; or 3) myocardial infarction, as evidenced by a rise in
serum creatine kinase, MB fraction to at least twice the normal
level or development of new Q waves on the electrocardiogram
within 24 h of the procedure. Patients with more than one
complication were counted only once.
The procedure type (combined vs. staged) was recorded for
all patients, and complete data for all potentially confounding
variables (Table 1), other than “multivessel disease,” were
available for 99% of patients. Detailed data on the variable
“multivessel disease” were available in the angioplasty data
bases for only 14,679 patients (41.1%) because the complete
information on coronary anatomy in all patients was recorded
in separate diagnostic catheterization data bases that could not
be linked to patient records in the angioplasty data bases.
Although information on the contrast volume used and arterial
time required for any PTCA was recorded, these data repre-
sented the total contrast volume and time required both for the
procedure and for the management of any complications
resulting from the procedure; because the amount of contrast
volume and arterial time recorded were thus determined by
the occurrence of complications, it was not appropriate to
include these variables as potential confounders in the analyses
of complications.
Abbreviations and Acronyms
ACC 5 American College of Cardiology
AHA 5 American Heart Association
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
OR 5 odds ratio
PTCA 5 percutaneous transluminal coronary
angioplasty
SCA&I 5 Society for Cardiac Angiography
and Interventions
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Statistical analysis. The univariate association between
PTCA timing (combined vs. staged) and major complications
was determined using odds ratios (ORs) with 95% confidence
intervals (CIs) and the chi-square or Fisher’s exact test. Staged
procedures were the reference group.
To determine if the effect of combined procedures on
outcomes was due to differences in characteristics of patients
treated with combined versus staged procedures, multivariable
logistic regression (18) was performed. Along with the timing
of PTCA, all variables in Table 1 (initially excluding multives-
sel disease) plus year of procedure were included in all models
to provide as complete control of confounding as possible (19).
In addition, the standard errors of the regression coefficients
were corrected for clustering by laboratory (20,21). A second-
ary analysis was also performed in which a series of indicator
variables for individual laboratories was included to assess the
effect of laboratory as a confounder. Separate models that
included multivessel disease also were derived in the subset of
patients with known multivessel disease status. Interactions
between PTCA timing and the prespecified risk groups were
assessed using the relevant product-term in the multivariable
models. The changes in complication risk and PTCA timing
over the 4 years of this study were assessed using the Mantel-
Haenszel test for linear association (18). To determine the
change in complication risk over time, the variable “year”
(which as a continuous variable demonstrated an inverse linear
association with complications in univariate analyses) was
included as a continuous variable in the multivariable models.
All statistical analyses were performed using the SPSS
(version 6.1) and Stata (version 5.0) statistical programs, and
statistical significance was defined as a two-sided p value
, 0.05.
Results
Patient and procedural characteristics. There were 6,152
combined procedures (17.2% of all elective PTCAs) per-
formed in the 4 years of this study. The proportion of
Table 1. Clinical Characteristics of Patients by Procedure Type
Clinical Characteristic
Total Sample
(n 5 35,700)
Procedure Type [% (no.) of pts]
Combined
(n 5 6,152)
Staged
(n 5 29,548) p Value*
Age .65 years 42.8 (15,272) 41.6 (2,561) 43.0 (12,711) 0.046
AMI within last 2 to 14 days 17.9 (6,391) 27.8 (1,711) 15.8 (4,680) , 0.0001
Aortic valve disease 0.1 (50) 0.6 (36) 0.04 (14) , 0.0001
Congestive heart failure 3.7 (1,327) 4.0 (244) 3.7 (1,083) 0.27
Chronic renal insufficiency 1.8 (626) 1.8 (108) 1.8 (518) 1.00
Dialysis 0.4 (160) 0.5 (30) 0.4 (130) 0.60
Diabetes mellitus 16.9 (6,020) 17.0 (1,047) 16.8 (4,973) 0.72
Geographic region† , 0.0001
Northeast 43.1 (15,377) 13.8 (2,120) 86.2 (13,257)
South 20.9 (7,446) 18.0 (1,338) 82.0 (6,108)
Midwest 23.1 (8,256) 24.3 (2,005) 75.7 (6,251)
West 1.9 (686) 34.3 (235) 65.7 (451)
Canada 10.9 (3,900) 11.6 (453) 88.4 (3,447)
South America 0.1 (35) 2.9 (1) 97.1 (34)
Graft attempted 4.7 (1,668) 4.3 (264) 4.8 (1,404) 0.13
Hypertension 40.3 (14,400) 42.5 (2,615) 39.9 (11,785) 0.0001
LMCA attempted 0.5 (162) 0.4 (25) 0.5 (137) 0.60
Laboratory volume #200 cases/year 12.1 (4,332) 15.4 (948) 11.5 (3,384) , 0.0001
Lytic therapy before PTCA 6.7 (2,403) 11.0 (674) 5.9 (1,729) , 0.0001
Mitral valve disease 0.4 (138) 1.7 (105) 0.1 (33) , 0.0001
Multilesion PTCA 24.7 (8,818) 18.8 (1,159) 25.9 (7,659) , 0.0001
Multivessel disease‡ 33.3 (4,891) 34.8 (1,851) 32.5 (3,040) 0.004
Previous CABG 10.8 (3,63) 10.2 (627) 11.0 (3,236) 0.075
Previous valve surgery 0.3 (103) 0.3 (21) 0.3 (82) 0.43
Unstable angina 35.2 (12,573) 42.5 (2,613) 33.7 (9,960) , 0.0001
Women 32.3 (11,529) 32.5 (2,001) 32.2 (9,528) 0.67
Worst lesion type attempted
Type A 36.5 (13,026) 36.8 (2,261) 36.4 (10,765) 0.018
Type B 50.6 (18,054) 51.4 (3,162) 50.4 (14,892)
Type C 12.9 (4,620) 11.8 (729) 13.2 (3,891)
*Chi-square test for differences in clinical characteristics between combined and staged procedures. †Percentages are row percentages for geographic region (e.g.,
13.8% of coronary angioplasties performed in the Northeast were done during a diagnostic catheterization). Geographic region was defined as in a previous study (1).
‡For subset of patients with known multivessel disease status (n 5 14,769). AMI 5 acute myocardial infarction; CABG 5 coronary artery bypass graft surgery; LMCA 5
left main coronary artery; PTCA 5 percutaneous transluminal coronary angioplasty; pts 5 patients.
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combined procedures performed per year in any one labora-
tory ranged from 0% to 86%, and there was an increase in the
proportion of combined procedures from 13.6% in 1992 to
22.5% in 1995 (p , 0.0001) (Fig. 1). An increasing proportion
was also found when the analysis was restricted to laboratories
contributing data to all 4 years (p , 0.0001), suggesting that
the proportion of combined procedures increased within lab-
oratories, not that laboratories that did more combined pro-
cedures entered the Registry in later years.
The clinical characteristics differed between patients under-
going combined versus staged procedures (Table 1). Although
some potential risk factors were more prevalent in patients
undergoing combined procedures (e.g., multivessel disease,
unstable angina, lower laboratory volume, aortic valve disease
and recent infarction or thrombolytic therapy), others were
more prevalent in patients undergoing staged procedures (e.g.,
older age, multilesion PTCA and complex lesion PTCA).
Relation between PTCA timing and outcomes. The overall
risks of complications were mortality 0.2%, emergency CABG
1.1%, AMI 0.5% and major complications 1.6%. In unadjusted
analyses, there was a statistically significant 28% greater
relative risk of major complications (a 0.4% absolute risk
difference) from combined procedures compared with staged
procedures in all patients (Table 2), and a 35% greater relative
(0.6% absolute) risk in the subset of patients with known
multivessel disease status (OR 1.35, 95% CI 1.06 to 1.72).
There was no significant difference in the OR for combined
procedures in those with known multivessel disease status
compared with those with unknown status (multivariable p 5
0.2 for interaction). After adjusting for the year, the effects of
clustering on laboratory and all variables in Table 1 except
multivessel disease, there was no detectable association be-
tween PTCA timing and complications (OR 1.18, 95% CI 0.89
to 1.55) (Table 2). Including multivessel disease in the model
produced similar results (OR 1.23, 95% CI 0.95 to 1.58). In a
model that corrected for clustering but that did not adjust for
confounders, the OR was 1.28 (95% CI 0.92 to 1.80), and in a
model adjusting for confounders but that did not correct for
clustering, the OR was 1.21 (95% CI 0.99 to 1.49). In the
analysis that included indicator variables for laboratory as
covariates, the OR was 0.89 (95% CI 0.70 to 1.12). The test for
an interaction between laboratory and PTCA timing was not
significant (p 5 0.9), indicating that the relative risk of
combined versus staged procedures was statistically indistin-
Figure 1. Percentage of all procedures that
were done as combined percutaneous translu-
minal coronary angioplasty (PTCA) in each
year.
Table 2. Univariate and Multivariable Association Between Outcomes and Procedure Type
Outcome
OR (95% CI)
Incidence (%) in
Combined Procedures
(n 5 6,152)
Incidence (%) in
Staged Procedures
(n 5 29,548)
Univariate OR for
Combined Relative to
Staged Procedures
Multivariable
OR*
In-hospital death 0.29 (0.17–0.46) 0.16 (0.12–0.21) 1.84 (1.07–3.17) 1.62 (0.90–2.93)
Emergent CABG 1.34 (1.07–1.66) 1.09 (0.98–1.22) 1.22 (0.96–1.56) 1.15 (0.86–1.56)
AMI 0.73 (0.54–0.98) 0.15 (0.11–0.70) 1.56 (1.11–2.18) 1.40 (0.72–2.72)
Major complication 2.01 (1.67–2.39) 1.57 (1.43–1.71) 1.28 (1.05–1.57) 1.18 (0.89–1.55)
*All variables in Table 1 are in the model, except for multivessel disease, and confidence intervals are adjusted for clustering by laboratory. CI 5 confidence interval;
OR 5 odds ratio; other abbreviations as in Table 1.
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guishable from laboratory to laboratory. Similar to the results
using the composite outcome of major complications, there
was a statistically significant increased risk of death and AMI
from combined procedures in univariate but not multivariable
analyses (Table 2).
Risk in subgroups of patients. There was no significant
difference in the risk of combined procedures relative to staged
procedures when patients were stratified by annual procedural
volume in the laboratory performing the PTCA or by the
presence or absence of a recent infarction, congestive heart
failure, diabetes mellitus, unstable angina and complex lesion
type (type A vs. B or C) PTCA (all tests for interaction p .
0.10). In addition, none of these individual low or high risk
subgroups exhibited a significant difference in risk from com-
bined compared with staged procedures.
However, the relative risks of combined versus staged
procedures did differ by age, gender, multivessel disease status
and number of lesions attempted (Table 3). Older patients had
an increased risk from combined relative to staged procedures
that was different from younger patients (test for interaction
p 5 0.057 when multivessel disease was excluded from the
model and p 5 0.020 when multivessel disease was included).
The multivariable OR from combined procedures in patients
.65 years old was significantly elevated whether multivessel
disease was included in the model (Table 3) or not (OR 1.52,
95% CI 1.09 to 2.10). The increased risk in older patients was
also statistically indistinguishable across the 4 years of the
study (multivariable p 5 0.11 for interaction by year).
Women also had an increased relative risk from combined
procedures that was significantly different (interaction p 5
0.02) from the risk in men. The OR from combined procedures
relative to staged procedures was significantly elevated in
women but not in men (Table 3). This increased risk persisted
in women when further adjusting for multivessel disease in the
subset of patients with known multivessel disease status (OR
1.84, 95% CI 1.24 to 2.72). The increased risk in women was
statistically indistinguishable across the 4 years of the study
(multivariable p 5 0.09 for interaction).
The OR in multilesion PTCA was significantly elevated and
was different from the OR in single-lesion PTCA (Table 3).
After adjusting for multivessel disease status, the relation
persisted (test for interaction p 5 0.15, multivariable OR 1.63
in multilesion PTCA, 95% CI 1.04 to 2.57). The risk from
multilesion PTCA was statistically indistinguishable across the
4 years of the study (multivariable p 5 0.40 for interaction).
Similarly, the OR for combined procedures in patients with
multivessel disease was both significantly elevated and signifi-
cantly different (p 5 0.031) from the OR in patients with
single-vessel disease (Table 3). The multivariable ORs in
patients with multivessel disease were similar in each year of
the study (multivariable p 5 0.80 for interaction). In those
patients with multivessel disease undergoing ad hoc multile-
sion PTCA, the risk of complications was more than twofold
greater compared with similar patients undergoing staged
procedures (multivariable OR 2.30, 95% CI 1.34 to 3.98).
Change in patient group and complication risk over time by
procedure type. The prevalence of several risk factors for com-
plications (diabetes mellitus, recent infarction, complex lesion
PTCA and unstable angina) increased in patients undergoing
both combined and staged procedures over the 4 years of the
study (all p values ,0.01). The mean age increased somewhat
(p , 0.01), and the prevalence of multivessel disease increased
dramatically (23% in both 1992 and 1993 and 47% in 1994 and
1995; p , 0.0001) in staged procedures but not in combined
procedures (p 5 0.54 for age; p 5 0.88 for multivessel disease).
Women were somewhat more likely to undergo combined (p 5
0.05) but not staged (p 5 0.23) procedures in later years.
There was a significant overall decrease in the risk of major
complications over time (1.9% in 1992, 1.7% in 1993, 1.4% in
1994 and 1.5% in 1995; test for trend p 5 0.006). Although the
Table 3. Association of Procedure Type With Major Complications for Different Risk Groups of Patients*
Risk Group
Procedure Type [% (no.) of pts with major complications] OR for Combined
Relative to Staged
Procedures
(95% CI)*
p Value for Test for
Interaction†
Combined
(n 5 6,152)
Staged
(n 5 29,548)
Total patients (n 5 18,568) 2.0 (123) 1.6 (463) 1.18 (0.89–1.55)
Age 0.057
#65 years (n 5 20,409) 1.7 (62) 1.6 (264) 1.02 (0.73–1.41)
.65 years (n 5 15,272) 2.4 (61) 1.6 (199) 1.40 (1.02–1.93)
Gender 0.02
Female (n 5 11,529) 2.6 (52) 1.5 (141) 1.64 (1.05–2.55)
Male (n 5 24,171) 1.7 (71) 1.6 (322) 0.98 (0.75–1.28)
Multivessel disease‡ 0.03
Yes (n 5 4,891) 3.0 (55) 1.6 (49) 1.64 (1.13–2.39)
No (n 5 9,788) 1.7 (60) 1.6 (102) 1.02 (0.76–1.37)
Number of lesions attempted 0.11
One (n 5 26,882) 1.9 (93) 1.6 (345) 1.09 (0.80–1.49)
More than one (n 5 8,818) 2.6 (30) 1.5 (118) 1.53 (1.06–2.21)
*Only statistically significant results are shown (see text for results of all subgroups). †Adjusted for all other variables in Table 1, except for multivessel disease,
and adjusted for clustering by laboratory. ‡For subset of patients with known multivessel disease status. Abbreviations as in Tables 1 and 2.
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absolute risk from combined procedures decreased over time
(multivariable p , 0.001), the risk did not decrease from
staged procedures over time (multivariable p 5 0.13) (Fig. 2).
Consequently, the relative risk decreased over time; for each
year of the study, the multivariable ORs (95% CIs) for major
complications from combined versus staged procedures de-
creased: 1.43 (0.89 to 2.30), 1.32 (0.80 to 2.20), 1.16 (0.75 to
1.78) and 0.70 (0.44 to 1.09) in 1992, 1993, 1994 and 1995,
respectively. This decrease in relative risk was statistically
significant when adjusting for laboratory and all variables in
Table 1 except multivessel disease (test for linear interaction of
procedure timing by year p 5 0.029; regression coefficient
20.1740 for interaction term). When also adjusting for mul-
tivessel disease in the smaller subset of patients with known
multivessel disease status, the test for interaction was no longer
statistically significant (p 5 0.24), although the regression
coefficient was similar (20.1156). Limiting the analyses to only
those laboratories that contributed data to all 4 years of the
study did not substantively change any of the aforementioned
results.
Discussion
Association between combined procedures and complica-
tions. In this study, combined procedures were not associated
with a greater risk of major complications than staged proce-
dures after accounting for 1) differences in the clinical charac-
teristics of patients undergoing these procedures and 2) clus-
tering of outcomes by laboratories. Furthermore, there was no
evidence for interlaboratory variability in the relative risk of
combined procedures. An increased risk was also observed for
each of the specific outcomes, but, again, after appropriate
multivariable adjustments these associations were no longer
statistically significant.
This overall negative conclusion must be viewed cautiously,
however. It is not known what factors minimize the risk of
combined procedures or were responsible for the decrease in
risk over time. Other, more intangible variables such as
individual operator experience and catheterization laboratory
“systems” (e.g., algorithms, clinical pathways) were not in-
cluded in the present data base but may be critically important
in ensuring the safety of combined procedures.
Risk in subgroups. In addition, the risk of combined
procedures may be increased in certain subgroups of patients.
The data suggest that older patients, women, patients with
multivessel disease and patients undergoing multilesion PTCA
(all prespecified subgroups) may be at increased risk from
combined relative to staged procedures. In the absence of
further studies, one can only speculate why this may be so.
Combined procedures may increase the risk in these subgroups
if the risk or technical difficulty of performing PTCA in these
patients is not as well appreciated during combined procedures
as during staged procedures (e.g., if cine films are not critically
reviewed before angioplasty) or if the performance of a
combined procedure results in increased contrast load, more
intimal disruption and destabilization of plaque (22,23) and/or
inadequate maintenance of anticoagulation or antiplatelet
therapy throughout the course of treatment (24–26).
For example, women may be at increased risk because the
smaller vessel size in women (27,28) may lead to a higher
likelihood of improper balloon sizing or failure to recognize
lesion complexity when relying on non–cine film techniques
Figure 2. Risk of major complica-
tions (%) by year among patients
undergoing coronary angioplasty in
all participating laboratories.
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with lesser resolution (29,30) during a combined procedure. It
is also possible that, because of women’s smaller body surface
area, the amount of contrast used in combined procedures
represents an excessive dye load. Similarly, multilesion PTCAs
in patients with multivessel disease represent more complex,
prolonged procedures; performing them immediately after a
diagnostic catheterization could increase the risk if the tech-
nical difficulty is not appreciated before proceeding or if the
procedure requires excessive time and contrast dye loads.
Similar arguments can be made for older patients.
Change in complication risk over time. There was a signif-
icant decrease in the absolute risk of complications from ad
hoc PTCAs over the 4 years encompassed by this study, despite
their use in higher risk patients. Equally important, there was
a decrease in the relative risk of combined compared with
staged procedures over time. This suggests that improvements
in technical abilities, equipment, procedural protocols and/or
patient selection procedure may also be important to ensuring
the safety of combined PTCA. Our data do not allow us to
explore the reasons for this improvement in outcomes, and
further studies to determine what factors improve the safety of
same-sitting PTCAs will be important to ensure continued
improvement in patient outcomes.
Comparison with other studies. Although previous studies
have suggested that performing PTCA early after the onset of
unstable angina increases the risk of complications compared
with delaying the procedure (25,31,32), no studies that have
directly compared combined with staged procedures have
shown an increased risk from combined procedures. However,
many of these later studies focused on carefully selected
groups of patients with unstable angina (6,7) or included only
repeat PTCAs (33) in which the benefits of known anatomy
and previous experience might make combined procedures as
safe as staged procedures. Several studies also used specific
protocols for combined procedures that required careful as-
sessment of coronary anatomy, patient risk and appropriate-
ness of PTCA before proceeding with the procedure (8,9). In
addition, previous studies were of small size and thus could not
exclude the possibility of a clinically significant increase in risk
from combined procedures. For example, the largest study to
date (8) could not exclude a relative risk as high as 2.0 (based
on our calculations of the 95% CI). Finally, no previous study
has included analyses that adjust for differences in clinical and
anatomic characteristics.
Our large, multicenter study included most patients under-
going a first balloon PTCA, excluding only 13% of first
angioplasties because they occurred in patients who were
clinically unstable, required an emergency PTCA or underwent
angioplasty as therapy within 24 h of an AMI. Thus, across
numerous clinical settings and laboratories, combined proce-
dures were not independently associated with an increased risk
of complications, except in the subgroups described. It is
important to note that 71% of all patients had at least one risk
factor for increased risk from combined PTCA (age .65 years,
female gender, multivessel disease or multilesion PTCA).
Thus, increasing the overall use of combined PTCAs, particu-
larly in these groups of patients, could increase the number of
complications attributable to this protocol.
Study limitations. There are several important limitations
to this study. First, the finding of increased risk in subgroups of
patients must be interpreted cautiously because they were
observed among numerous subgroup analyses in the setting of
an overall negative finding. Nonetheless, these subgroups were
specified in advance, and the increased risk is both biologically
plausible and consistent over the 4 years of the study, suggest-
ing that these findings are valid and that a substantial propor-
tion of patients may not be appropriate for combined proce-
dures. Second, although the results cannot necessarily be
generalized to patients requiring PTCA for restenosis or for
conditions refractory to medical therapy, these patients would
be expected to be particularly suited for combined procedures,
as outlined in the ACC/AHA guidelines (5). Importantly, our
results should be applicable to the majority of patients under-
going a first balloon angioplasty, as 87% of all patients
undergoing their first angioplasty in participating laboratories
were included. It will, of course, be important for future studies
to assess the effects of new devices and adjuvant therapies such
as stents and IIb/IIIa inhibitors on the relative risk of com-
bined versus staged procedures, particularly in high risk pa-
tients. Third, differential misclassification of outcomes (“gam-
ing”) could bias the results if laboratories doing more
combined procedures tended to underrepresent their compli-
cations, thus underestimating the true association between
combined procedures and complications. We believe that this
is unlikely because the SCA&I Registry data base is confiden-
tial and is not used by external auditors. Fourth, combined
procedures included complications from both angiography and
angioplasty, whereas staged procedures included complica-
tions only from angioplasty. However, the rate of major
complications that are attributable to diagnostic angiography is
extremely low (12), and patients with complications of diag-
nostic angiography requiring PTCA were excluded from this
study. Thus, this would be unlikely to bias the results in favor
of staged procedures.
Conclusions. Given the enormous pressure for the medical
care system to become more cost efficient, performance of
combined procedures has been advocated as a means to reduce
costs (3,4,8,9) and is likely to be increasingly encouraged by
health care payers and providers. This study suggests that
performing PTCA at the time of the diagnostic catheterization
is, overall, as safe as performing it later and that the procedure
has become safer over time. However, there are subgroups that
may be at greater risk with this strategy. In particular, perform-
ing more complex procedures such as multivessel PTCA or
PTCA in patients with multivessel disease at the same time as
the diagnostic procedure appears to be associated with an
increased risk of complications. The risk of the combined
procedure also appears higher in older patients and in women.
Further study is needed to confirm these findings. In the
meantime, proper patient selection for combined PTCA and
continued consideration of the other risks and benefits of
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combined PTCA is likely to remain important in assuring the
continued safety of this procedure.
We thank Sandra Barile for assistance with document preparation.
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